Xcout Intel
Congruence Therapeutics
Congruence Therapeutics is a clinical-stage biotechnology company located in Montreal, Quebec, that discovers and develops small molecule correctors and allosteric modulators for protein-misfolding diseases.
Subscribe to see Congruence Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Congruence Therapeutics at a glance
Congruence Therapeutics is a biotechnology company headquartered in Canada. It has raised at least $115M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $65M in March 2023. Xcout tracks 21 named people at Congruence Therapeutics, including Clarissa Desjardins (CEO).
Congruence Therapeutics leadership
- Clarissa DesjardinsCEO
- Charles GrubsztajnCOO
- Frank TaffyCBO
- Michael D. HarveyCDO
- Sharath HegdeCSO
- Michael Rock GoldsmithChief Innovation Scientist
15 more named people on record for Congruence Therapeutics, with roles, board committees and tenure — see the full roster →
Congruence Therapeutics funding rounds
At least $115M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 3 named | |
| Series A | $50M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Congruence Therapeutics competitors
A few of Congruence Therapeutics's closest competitors — see the full list of competitors and alternatives →
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Octant Bio is a biotechnology company that combines next-generation biology, chemistry, and computation to discover and develop precision small molecule therapeutics. The company targets complex cellular mechanisms to address genetic diseases, such as protein misfolding and mistrafficking across various therapeutic areas including genetic disorders, oncology, metabolism, and immunology.
KisoJi Biotechnology Inc. is a drug discovery company headquartered in Montreal, Canada, utilizing a proprietary antibody discovery platform to create next-generation antibody drugs.
Sharp Therapeutics Corp. is a preclinical-stage biotechnology and drug discovery company that develops small molecule therapies to treat genetic diseases and hereditary disorders. The company combines high-speed experimentation and computational methods to advance its drug discovery platform.
Cerevance is a pharmaceutical and biotechnology research company based in Boston, Massachusetts, that uses its proprietary NETSseq platform to develop cell-type specific treatments. The company focuses on neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Get Congruence Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Congruence Therapeutics in Xcout Intel
- 21 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access